Aua Capital Management LLC decreased its stake in Pfizer, Inc. (NYSE:PFE) by 63.2% during the first quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 3,025 shares of the biopharmaceutical company’s stock after selling 5,200 shares during the period. Aua Capital Management LLC’s holdings in Pfizer were worth $103,000 as of its most recent filing with the SEC.
Other hedge funds and other institutional investors have also recently bought and sold shares of the company. Independent Advisor Alliance purchased a new position in Pfizer during the fourth quarter valued at $1,385,000. DZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am Main purchased a new position in Pfizer during the fourth quarter valued at $289,666,000. Lebenthal Asset Management LLC increased its position in Pfizer by 0.5% in the fourth quarter. Lebenthal Asset Management LLC now owns 164,776 shares of the biopharmaceutical company’s stock valued at $5,352,000 after buying an additional 778 shares during the last quarter. RB Capital Management LLC purchased a new position in Pfizer during the fourth quarter valued at $321,000. Finally, Santa Barbara Asset Management LLC increased its position in Pfizer by 7.7% in the fourth quarter. Santa Barbara Asset Management LLC now owns 4,328,169 shares of the biopharmaceutical company’s stock valued at $140,579,000 after buying an additional 309,883 shares during the last quarter. Institutional investors own 69.94% of the company’s stock.
Pfizer, Inc. (PFE) traded down 0.85% during mid-day trading on Friday, hitting $32.67. The company’s stock had a trading volume of 15,490,145 shares. The company’s 50 day moving average is $33.30 and its 200-day moving average is $33.38. Pfizer, Inc. has a 52-week low of $29.83 and a 52-week high of $35.38. The stock has a market cap of $194.30 billion, a P/E ratio of 23.90 and a beta of 1.00.
Pfizer (NYSE:PFE) last released its quarterly earnings data on Tuesday, August 1st. The biopharmaceutical company reported $0.67 earnings per share for the quarter, topping analysts’ consensus estimates of $0.65 by $0.02. The firm had revenue of $12.90 billion during the quarter, compared to analyst estimates of $13.08 billion. Pfizer had a return on equity of 24.51% and a net margin of 15.84%. The business’s quarterly revenue was down 1.9% compared to the same quarter last year. During the same quarter in the prior year, the company posted $0.64 earnings per share. On average, equities analysts predict that Pfizer, Inc. will post $2.56 EPS for the current fiscal year.
The firm also recently disclosed a quarterly dividend, which will be paid on Friday, September 1st. Stockholders of record on Friday, August 4th will be paid a $0.32 dividend. This represents a $1.28 dividend on an annualized basis and a dividend yield of 3.92%. The ex-dividend date is Wednesday, August 2nd. Pfizer’s dividend payout ratio (DPR) is 94.12%.
Several research firms have recently weighed in on PFE. BidaskClub upgraded Pfizer from a “strong sell” rating to a “sell” rating in a research note on Friday, June 23rd. BMO Capital Markets reiterated a “hold” rating and set a $33.00 price target on shares of Pfizer in a research note on Thursday, April 27th. Sanford C. Bernstein reiterated a “buy” rating and set a $35.00 price target on shares of Pfizer in a research note on Monday, April 24th. Credit Suisse Group downgraded Pfizer from an “outperform” rating to a “neutral” rating and cut their price target for the stock from $38.00 to $36.00 in a research note on Thursday, July 20th. Finally, Barclays PLC reiterated a “buy” rating and set a $38.00 price target on shares of Pfizer in a research note on Wednesday, May 3rd. Two investment analysts have rated the stock with a sell rating, eleven have assigned a hold rating and ten have assigned a buy rating to the company’s stock. Pfizer presently has a consensus rating of “Hold” and an average price target of $37.61.
In related news, insider Alexander R. Mackenzie sold 15,000 shares of the business’s stock in a transaction dated Monday, August 7th. The stock was sold at an average price of $33.50, for a total value of $502,500.00. Following the sale, the insider now directly owns 151,474 shares in the company, valued at $5,074,379. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, CEO Ian C. Read sold 96,950 shares of the business’s stock in a transaction dated Friday, August 4th. The stock was sold at an average price of $34.00, for a total value of $3,296,300.00. The disclosure for this sale can be found here. Corporate insiders own 0.06% of the company’s stock.
Pfizer Inc (Pfizer) is a research-based global biopharmaceutical company. The Company is engaged in the discovery, development and manufacture of healthcare products. Its global portfolio includes medicines and vaccines, as well as consumer healthcare products. The Company manages its commercial operations through two business segments: Pfizer Innovative Health (IH) and Pfizer Essential Health (EH).
Receive News & Ratings for Pfizer Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer Inc. and related companies with MarketBeat.com's FREE daily email newsletter.